Moosmann Thomas, Veraar Cécilia, Brunner Jürgen, Fraedrich Gustav, Frech Andreas, Horninger Wolfgang, Ratzinger Gudrun, Streif Werner, Teuchner Barbara, Willeit Johann, Zlamy Manuela, De Zordo Tobias, Schirmer Michael
Department of Internal Medicine, Clinic II, Medizinische Universität Innsbruck, Innsbruck, Austria.
Department of Pediatrics, Clinic I, Medizinische Universität Innsbruck, Innsbruck, Austria.
Int J Rheum Dis. 2018 Dec;21(12):2151-2157. doi: 10.1111/1756-185X.13306. Epub 2018 Apr 17.
To assess demographical and clinical data in a Middle-European cohort of patients with Adamantiades-Behçet's disease (ABD), together with the use of medication in adherence to international guidelines.
In a retrospective cohort study, in- and outpatients of an Austrian secondary and tertiary university hospital center were analyzed independent from the medical discipline involved. After ethics approval, screening for ABD-patients in the clinical information system resulted in 1821 documents from 1997 to 2016. Patients fulfilling the International Criteria for Behçet's Disease were included, and ABD symptoms and signs together with medical interventions for immunosuppression, anticoagulation and pain management were identified by individual chart reviews and evaluated for conformity with international recommendations.
A total of 76 ABD patients were identified with 39.1% Austrian and 37.0% Turkish origin. Genital aphthae and skin manifestations were more frequent, neurological, gastrointestinal and vascular manifestations less frequent in ABD patients of Turkish origin living in Austria compared to those living in Turkey (each P < 0.05). The male-to-female ratio averaged 0.86 (0.39 in patients with Austrian and 1.43 with Turkish backgrounds), and was 3.3 in patients with venous manifestations. Out of 174 medical interventions, 55.2% fully matched the European League Against Rheumatism recommendations of 2008, and 93.7% were considered at least as equal to the recommendations. Indications for tumor necrosis factor inhibition were in line with the 2007 Sfikakis recommendations.
In this Middle-European ABD cohort clinical presentations between patients of Austrian and Turkish origin do not strongly vary, whereas Turkish patients from the non-endemic Innsbruck cohort present differently compared to patients living in Turkey. The role of such cohort analyses will increase, from the epidemiological as well as the management perspective.
评估中欧地区一组白塞病（ABD）患者的人口统计学和临床数据，以及遵循国际指南的用药情况。
在一项回顾性队列研究中，对奥地利一家二级和三级大学医院中心的门诊和住院患者进行分析，不受所涉及医学学科的影响。经伦理批准后，在临床信息系统中筛查ABD患者，得到1997年至2016年的1821份文档。纳入符合白塞病国际标准的患者，通过个人病历审查确定ABD症状和体征以及免疫抑制、抗凝和疼痛管理的医疗干预措施，并评估其是否符合国际建议。
共确定76例ABD患者，其中39.1%为奥地利裔，37.0%为土耳其裔。与生活在土耳其的患者相比，生活在奥地利的土耳其裔ABD患者中生殖器溃疡和皮肤表现更为常见，神经、胃肠和血管表现则较少见（均P<0.05）。男女比例平均为0.86（奥地利背景患者为0.39，土耳其背景患者为1.43），有静脉表现的患者中该比例为3.3。在174项医疗干预措施中，55.2%完全符合2008年欧洲抗风湿病联盟的建议，93.7%被认为至少等同于该建议。肿瘤坏死因子抑制的适应证符合2007年斯菲卡基斯的建议。
在这个中欧ABD队列中，奥地利裔和土耳其裔患者的临床表现差异不大，而来自非流行地区因斯布鲁克队列的土耳其患者与生活在土耳其的患者表现不同。从流行病学和管理角度来看，此类队列分析的作用将不断增加。
